Enabling exploitation of novel reagents and assays (EnRgy) to target the inhibition of peptidoglycan biosynthesis
Lead Research Organisation:
University of Warwick
Department Name: School of Life Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
N/A
Planned Impact
N/A
Publications
Vajs J
(2017)
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
in European journal of medicinal chemistry
Tran AT
(2017)
Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.
in Nature communications
Dougan G
(2019)
Meeting the discovery challenge of drug-resistant infections: progress and focusing resources.
in Drug discovery today
Catherwood AC
(2020)
Substrate and Stereochemical Control of Peptidoglycan Cross-Linking by Transpeptidation by Escherichia coli PBP1B.
in Journal of the American Chemical Society
| Description | Knowledge transfer from the pharmaceutical antibiotic discovery industry to academia and vice versa. More effective approaches to industry |
| Exploitation Route | Additional support for academic and industrial leave and engagement |
| Sectors | Education,Pharmaceuticals and Medical Biotechnology |
| Description | They have informed global pharma, given them new insight and new approaches for antibiotic discovery, including the development of new screening capabilities in the form of reagents and assays |
| First Year Of Impact | 2014 |
| Sector | Aerospace, Defence and Marine,Education,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | Chair of Scientific Committee Antibiotic Research Uk |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Patient focussed dialogue regarding antibiotic effectiveness and patient informed research |
| URL | https://www.antibioticresearch.org.uk |
| Description | Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery |
| Amount | £1,000,000 (GBP) |
| Funding ID | MR/P007503/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 05/2019 |
| Description | Coventry General Charities |
| Amount | £40,000 (GBP) |
| Organisation | General Charity of the City of Coventry |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 01/2015 |
| Description | Coventry General Charities |
| Amount | £157,000 (GBP) |
| Organisation | General Charity of the City of Coventry |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2018 |
| End | 09/2022 |
| Description | MRC AMR theme 1 collaboration award |
| Amount | £3,200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 03/2021 |
| Description | Wellcome Trust Innovation Award |
| Amount | £100,000 (GBP) |
| Funding ID | 109676/Z/15/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 06/2017 |
| Description | Astra Zeneca global screening platform |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Knowledge transfer, biological insight and assay development |
| Collaborator Contribution | Advice, knowledge transfer, training and access to high throughput screening platforms and chemical libraries |
| Impact | Novel assay development and assay validation Hit screening underway |
| Start Year | 2013 |
| Description | Entasis collaboration |
| Organisation | Entasis Therapeutics |
| Country | United States |
| Sector | Private |
| PI Contribution | Biochemistry and assay development |
| Collaborator Contribution | Assay validation and hit characterisation insight |
| Impact | Successful award of Wellcome Trust Pathfinder award |
| Start Year | 2015 |
| Description | Warwick Oxford Chemistry Collaboration |
| Organisation | University of Oxford |
| Department | Department of Paediatrics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Providing underpinning assays to help inform antibiotic development approaches..................................... |
| Collaborator Contribution | Chemistry input and design |
| Impact | Multidisciplinary |
| Start Year | 2014 |
| Title | Synthesis of peptidoglycan intermediates |
| Description | Optimisation of peptidoglycan pathway intermediates synthesis and purification |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2006 |
| Licensed | No |
| Impact | Development of a synthesis facility to provide thes eintemediates to the global research community and the fundamental platform for several UK and international peptidoglycan networks |
| Company Name | Antimicrobial Discovery Solutions Ltd |
| Description | Reagents, assay development and services |
| Year Established | 2015 |
| Impact | N/A |
| Description | ANTRUK Antibiotic Research UK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | Yes |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Establishment of new charity and new fundraising campaign regional and national media interest |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://www.antibioticresearch.org.uk |
| Description | Establishment of Medicines discovery Catapult Facility |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | World-class technology and expertise are now available to UK drug discovery companies as a result of new laboratory facilities developed by the Medicines Discovery Catapult - launched on Wednesday 29th March at the University of Warwick. Catapult open for business with £1m investment in cutting-edge lab capacity to support UK drug discovery https://warwick.ac.uk/newsandevents/pressreleases/catapult_open_for/ |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://vimeo.com/211376977 |
| Description | MRC Flemming video |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | Yes |
| Type Of Presentation | Keynote/Invited Speaker |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | 100000. Short film presentation linking our current MRC funded research to the groundbreaking work by alexander Flemming to be released later this year as part of the MRC celebrations |
| Year(s) Of Engagement Activity | 2013 |
| Description | O'Neil AMR review |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | In December we published our first report1 showing that infections caused by drug-resistant pathogens are one of the biggest health problems the world faces today. Bacteria and other pathogens have always evolved to resist the new drugs that modern medicine uses to combat them. But in recent years the rise in drug resistance has been a particular worry, especially the emergence of antibioticresistant superbugs. Unless action is taken to address this huge global issue, our conservative estimate is that it will cost the world an additional 10 million lives a year by 2050, more than the number of people currently dying from cancer annually. It will also have a cumulative cost of 100 trillion USD, more than one and a half times annual world GDP today, or roughly the equivalent to losing the UK economy from global output every year. We now turn our attention to how this problem can be tackled. This paper is the first in a series that works towards global and sustainable solutions. There are many angles to the problem that we will need more time to consider. In particular, the focus of our next paper, due to be published in the spring, will be how to stimulate the market for companies to invest in and develop new antimicrobials and diagnostics, which is not fully addressed here. There we will assess potential 'push' and 'pull' incentives to encourage the development of new antimicrobial drugs, and set out our proposals for action by policy makers. In later papers we will also focus on important issues such as the use of antibiotics in agriculture and potential alternatives to antimicrobials |
| Year(s) Of Engagement Activity | 2015 |
| URL | https://amr-review.org/sites/default/files/Report-52.15.pdf |
| Description | Pew Road Map for Antibiotic Discovery |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a concrete approach-both a scientific plan and organizational structure to support this research-that would lay a foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the coming decades.The report's key findings show a need for: • A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development. • A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria, which cause some of the most difficult-to-treat infections. • Generation of new chemical matter designed for antibiotic discovery. • Tools and methodologies to evaluate promising alternatives to traditional antibiotic use. • A framework for sharing information, expertise, and materials across the research community to foster innovative science and spur the discovery of novel antibacterial therapies. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf |
| Description | Radio 4 3 part drama production |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Radio drama highlighting factors driving antibiotic resistance and global consequences - raising public awareness at the National level |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.bbc.co.uk/programmes/b08g7y1l |
| Description | School visit |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | 20 questions panel followed by open discussion around - what is a scientist Invited to attend further activities by the schools career department |
| Year(s) Of Engagement Activity | 2014 |
| Description | Trustee for a regional science charity MLS |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Development and distribution of new literature Inspired fund raising |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.charitychoice.co.uk/medical-and-life-sciences-research-fund-25719 |
| Description | University open day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Discussion around training and careers in microbiology an biomedical science Inspired about microbiology |
| Year(s) Of Engagement Activity | 2014 |